AI Tokens
Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

This company has been moved to the archive! The financial data has not been updated since May 2, 2024.

Analysis of Long-term (Investment) Activity Ratios

Microsoft Excel

Long-term Activity Ratios (Summary)

Zoetis Inc., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net fixed asset turnover 2.66 2.93 3.21 3.03 3.23
Net fixed asset turnover (including operating lease, right-of-use asset) 2.48 2.72 2.99 2.79 2.94
Total asset turnover 0.60 0.54 0.56 0.49 0.54
Equity turnover 1.71 1.83 1.71 1.77 2.31

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


The analysis of investment activity ratios reveals a divergence between the utilization of fixed assets and the efficiency of total asset and equity employment over the five-year period ending December 31, 2023.

Fixed Asset Utilization
A consistent downward trend is observed in both measures of fixed asset turnover. The net fixed asset turnover declined from 3.23 in 2019 to 2.66 in 2023, while the ratio including right-of-use assets dropped from 2.94 to 2.48 over the same period. Although a temporary recovery occurred in 2021, the subsequent declines in 2022 and 2023 suggest that the growth in fixed asset investment has outpaced the growth in generated revenue, resulting in lower asset productivity.
Total Asset Efficiency
In contrast to fixed assets, the total asset turnover remained relatively stable with a slight upward trajectory toward the end of the period. The ratio fluctuated between 0.49 and 0.60, reaching its peak of 0.60 in 2023. This stability indicates that the company has maintained a consistent ability to generate sales from its overall asset base, offsetting the declining efficiency observed in specific long-term fixed assets.
Equity Turnover
Equity turnover experienced a significant contraction between 2019 and 2020, falling from 2.31 to 1.77. Since 2020, the ratio has remained largely stagnant, ending at 1.71 in 2023. This pattern suggests a decrease in the efficiency of generating revenue relative to shareholder equity, which may be attributed to an increase in the equity base that has not been matched by a proportional increase in top-line growth.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Net Fixed Asset Turnover

Zoetis Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Revenue 8,544 8,080 7,776 6,675 6,260
Property, plant and equipment including finance lease right of use assets, less accumulated depreciation 3,213 2,753 2,422 2,202 1,940
Long-term Activity Ratio
Net fixed asset turnover1 2.66 2.93 3.21 3.03 3.23
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 10.89 11.76 11.00 — —
Amgen Inc. 4.53 4.57 4.69 — —
Bristol-Myers Squibb Co. 6.77 7.38 7.67 — —
Danaher Corp. 5.25 7.96 7.77 — —
Eli Lilly & Co. 2.64 2.81 3.15 — —
Gilead Sciences Inc. 5.07 4.93 5.27 — —
Johnson & Johnson 4.28 4.79 4.95 — —
Merck & Co. Inc. 2.61 2.77 2.53 — —
Pfizer Inc. 3.14 6.22 5.52 — —
Regeneron Pharmaceuticals Inc. 3.16 3.23 4.62 — —
Thermo Fisher Scientific Inc. 4.54 4.84 4.71 — —
Vertex Pharmaceuticals Inc. 8.51 8.06 6.92 — —
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.12 4.98 4.98 — —
Net Fixed Asset Turnover, Industry
Health Care 7.22 7.88 7.74 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Net fixed asset turnover = Revenue ÷ Property, plant and equipment including finance lease right of use assets, less accumulated depreciation
= 8,544 ÷ 3,213 = 2.66

2 Click competitor name to see calculations.


Analysis of the five-year period from 2019 to 2023 reveals a consistent increase in total revenue alongside an aggressive expansion of the company's fixed asset base. While revenue grew steadily, the rate of investment in property, plant, and equipment exceeded the rate of revenue growth, resulting in a gradual decline in asset utilization efficiency.

Revenue Trajectory
Revenue demonstrated a continuous upward trend, increasing from US$ 6,260 million in 2019 to US$ 8,544 million by the end of 2023. This represents a steady and uninterrupted expansion of the top line over the observed period.
Net Fixed Asset Expansion
Net property, plant, and equipment, including finance lease right-of-use assets, experienced significant growth, rising from US$ 1,940 million in 2019 to US$ 3,213 million in 2023. The investment in the asset base accelerated toward the end of the period, with a notable increase between 2022 and 2023.
Net Fixed Asset Turnover Efficiency
The net fixed asset turnover ratio shifted from 3.23 in 2019 to 2.66 in 2023. Despite a temporary recovery to 3.21 in 2021, the ratio has since followed a downward trajectory. This decline indicates that the company is generating progressively less revenue per unit of net fixed assets, suggesting that the scale of capital investment has outpaced the immediate generation of corresponding sales.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Zoetis Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Revenue 8,544 8,080 7,776 6,675 6,260
 
Property, plant and equipment including finance lease right of use assets, less accumulated depreciation 3,213 2,753 2,422 2,202 1,940
Operating lease right of use assets 230 220 181 192 189
Property, plant and equipment including finance lease right of use assets, less accumulated depreciation (including operating lease, right-of-use asset) 3,443 2,973 2,603 2,394 2,129
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 2.48 2.72 2.99 2.79 2.94
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 9.47 10.24 9.57 — —
Amgen Inc. 4.08 4.13 4.23 — —
Bristol-Myers Squibb Co. 5.60 6.18 6.66 — —
Danaher Corp. 4.26 6.35 6.10 — —
Eli Lilly & Co. 2.45 2.63 2.93 — —
Gilead Sciences Inc. 4.57 4.51 4.77 — —
Johnson & Johnson 4.07 4.54 4.72 — —
Merck & Co. Inc. 2.45 2.60 2.33 — —
Pfizer Inc. 2.72 5.25 4.64 — —
Regeneron Pharmaceuticals Inc. 3.11 3.17 4.52 — —
Thermo Fisher Scientific Inc. 3.89 4.13 3.98 — —
Vertex Pharmaceuticals Inc. 6.79 6.13 5.32 — —
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.71 4.48 4.45 — —
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 6.36 6.90 6.75 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property, plant and equipment including finance lease right of use assets, less accumulated depreciation (including operating lease, right-of-use asset)
= 8,544 ÷ 3,443 = 2.48

2 Click competitor name to see calculations.


The company demonstrates a steady increase in revenue and a corresponding growth in its net fixed asset base over the five-year period ending December 31, 2023. While total revenue rose from US$ 6,260 million in 2019 to US$ 8,544 million in 2023, the investment in property, plant, and equipment—including right-of-use assets—expanded more aggressively, rising from US$ 2,129 million to US$ 3,443 million.

Revenue and Asset Growth Trends
Revenue exhibited consistent growth throughout the period, resulting in a cumulative increase of approximately 36.5% between 2019 and 2023. During the same timeframe, net fixed assets increased by approximately 61.7%. This indicates that the expansion of the fixed asset base significantly outpaced the growth of top-line revenue.
Net Fixed Asset Turnover Analysis
The net fixed asset turnover ratio shows an overall downward trajectory, moving from 2.94 in 2019 to 2.48 in 2023. Although a temporary peak of 2.99 was reached in 2021, the ratio declined steadily in the subsequent two years. This pattern suggests a decrease in the efficiency with which the company utilizes its long-term physical assets to generate sales.
Operational Efficiency Insights
The decline in the turnover ratio from 2.99 in 2021 to 2.48 in 2023 highlights a growing gap between asset accumulation and revenue realization. The data suggests that recent investments in property, plant, and equipment have not yet translated into proportional revenue gains, which is often characteristic of a capacity expansion phase where assets are deployed before reaching full operational productivity.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Total Asset Turnover

Zoetis Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Revenue 8,544 8,080 7,776 6,675 6,260
Total assets 14,286 14,925 13,900 13,609 11,545
Long-term Activity Ratio
Total asset turnover1 0.60 0.54 0.56 0.49 0.54
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.40 0.42 0.38 — —
Amgen Inc. 0.28 0.38 0.40 — —
Bristol-Myers Squibb Co. 0.47 0.48 0.42 — —
Danaher Corp. 0.28 0.37 0.35 — —
Eli Lilly & Co. 0.53 0.58 0.58 — —
Gilead Sciences Inc. 0.43 0.43 0.40 — —
Johnson & Johnson 0.51 0.51 0.52 — —
Merck & Co. Inc. 0.56 0.54 0.46 — —
Pfizer Inc. 0.26 0.51 0.45 — —
Regeneron Pharmaceuticals Inc. 0.40 0.42 0.63 — —
Thermo Fisher Scientific Inc. 0.43 0.46 0.41 — —
Vertex Pharmaceuticals Inc. 0.43 0.49 0.56 — —
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.40 0.47 0.45 — —
Total Asset Turnover, Industry
Health Care 0.63 0.66 0.62 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Total asset turnover = Revenue ÷ Total assets
= 8,544 ÷ 14,286 = 0.60

2 Click competitor name to see calculations.


The analysis of investment activity between 2019 and 2023 reveals a sustained expansion in revenue coupled with a fluctuating asset base, leading to an overall improvement in asset utilization efficiency by the end of the period.

Revenue Trajectory
Revenue demonstrated consistent year-over-year growth, increasing from US$ 6,260 million in 2019 to US$ 8,544 million in 2023. This upward trend indicates a steady expansion in market reach or pricing power throughout the analyzed timeframe.
Asset Base Evolution
Total assets grew significantly between 2019 and 2022, rising from US$ 11,545 million to a peak of US$ 14,925 million. A contraction was observed in 2023, with assets decreasing to US$ 14,286 million, suggesting a shift toward asset optimization or a reduction in capital expenditure.
Total Asset Turnover Performance
The total asset turnover ratio experienced volatility, reaching a period low of 0.49 in 2020 before recovering. The ratio peaked at 0.60 in 2023, the highest value in the five-year sequence. The improvement in 2023 is particularly notable as it resulted from the convergence of rising revenues and a reduced asset base, signaling an increase in the efficiency with which the company generates sales from its investments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Equity Turnover

Zoetis Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Revenue 8,544 8,080 7,776 6,675 6,260
Total Zoetis Inc. equity 4,997 4,405 4,543 3,769 2,708
Long-term Activity Ratio
Equity turnover1 1.71 1.83 1.71 1.77 2.31
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 5.24 3.36 3.65 — —
Amgen Inc. 4.32 6.77 3.63 — —
Bristol-Myers Squibb Co. 1.53 1.49 1.29 — —
Danaher Corp. 0.45 0.63 0.65 — —
Eli Lilly & Co. 3.17 2.68 3.15 — —
Gilead Sciences Inc. 1.18 1.27 1.28 — —
Johnson & Johnson 1.24 1.24 1.27 — —
Merck & Co. Inc. 1.60 1.29 1.28 — —
Pfizer Inc. 0.67 1.06 1.06 — —
Regeneron Pharmaceuticals Inc. 0.51 0.54 0.86 — —
Thermo Fisher Scientific Inc. 0.92 1.02 0.96 — —
Vertex Pharmaceuticals Inc. 0.56 0.64 0.75 — —
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.15 1.24 1.27 — —
Equity Turnover, Industry
Health Care 1.69 1.69 1.67 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Equity turnover = Revenue ÷ Total Zoetis Inc. equity
= 8,544 ÷ 4,997 = 1.71

2 Click competitor name to see calculations.


Analysis of the financial performance between 2019 and 2023 indicates a steady increase in revenue alongside a general expansion of the equity base. While top-line growth remained consistent, the equity turnover ratio experienced an initial contraction followed by a period of relative stabilization.

Revenue Trends
Revenue demonstrated a consistent upward trajectory, increasing from 6,260 million US$ in 2019 to 8,544 million US$ by 2023. This represents a continuous growth pattern in sales volume or pricing power over the five-year period.
Equity Base Evolution
Total equity grew significantly from 2,708 million US$ in 2019 to 4,997 million US$ in 2023. A slight contraction was observed in 2022, where equity decreased to 4,405 million US$ from 4,543 million US$ in the previous year, before rebounding to its highest level in 2023.
Equity Turnover Analysis
The equity turnover ratio saw a notable decline from 2.31 in 2019 to 1.71 in 2021. This downward trend indicates that the growth in total equity outpaced the growth in revenue during the early part of the period, resulting in a lower efficiency of equity utilization. Between 2021 and 2023, the ratio stabilized, fluctuating between 1.71 and 1.83, suggesting that the rate of revenue growth began to align more closely with the expansion of the equity base.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?